Jack W Hsu1, Nam H Dang. Show Affiliations » 1. Affiliation of authors: Division of Hematology/Oncology, University of Florida, Gainesville, FL (JWH, NHD).
Abstract
Entities: Disease Gene
Mesh： See more » Activin Receptors, Type II/drug effectsActivin Receptors, Type II/metabolismAntineoplastic Agents/pharmacologyAntineoplastic Agents/therapeutic useBiomarkers, Tumor/metabolismBrentuximab VedotinCrizotinibDisease-Free SurvivalHumansImmunoconjugates/therapeutic useKi-1 Antigen/metabolismLymphoma, Large-Cell, Anaplastic/drug therapyLymphoma, Large-Cell, Anaplastic/metabolismLymphoma, Large-Cell, Anaplastic/prevention & controlMolecular Targeted Therapy/methodsPrognosisProtein Kinase InhibitorsPyrazoles/therapeutic usePyridines/therapeutic useSecondary PreventionTreatment Outcome
Substances： See more » Antineoplastic AgentsBiomarkers, TumorImmunoconjugatesKi-1 AntigenProtein Kinase InhibitorsPyrazolesPyridinesCrizotinibBrentuximab VedotinACVRL1 protein, humanActivin Receptors, Type II
Year: 2014 PMID： 24491304 DOI： 10.1093/jnci/djt454
Source DB: PubMed Journal: J Natl Cancer Inst ISSN： 0027-8874 Impact factor: 13.506